RxDoctor Payments Data

Kevin Slagoski, PA

Medical · Orlando, FLNPI 1851949432

Payments from drug & device makers

$3,453in general payments, 2019–2025

Across 84 payments — averaging $41.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • Boston Scientific$938
  • Endo Pharmaceuticals Inc.$396
  • Axonics, Inc.$128
  • Urovant Sciences Inc$100
  • Astellas Pharma US Inc$40
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$3,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,453 in reported general payments places this provider in the 80th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$41,836
Medicare patients
265
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron161$101,740
Tamsulosin Hcl108$2,190
Oxybutynin Chloride ErOxybutynin Chloride30$1,407
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip48$924
Tolterodine Tartrate ErTolterodine Tartrate19$822
Verapamil Hcl11$774
Finasteride39$711
Testosterone Cypionate21$664
Gabapentin75$601
Oxybutynin Chloride105$563
Doxycycline Hyclate67$504
Clobetasol EmollientClobetasol Propionate/Emoll12$466
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$450
Alfuzosin Hcl ErAlfuzosin Hcl20$412
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim70$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$40$101,740161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,031 medical providers in Florida.

Other medical in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →